Purified eicosapentaenoic acid (EPA) and mixed eicosapentaenoic/docosahexaenoic acids (EPA/DHA), the major constituents of fish oil, are omega-3 (n-3) polyunsaturated fatty acids (PUFAs) of interest for their antiatherogenic effects in the prevention of cardiovascular disease (CVD).1 Several randomized clinical trials (RCTs) have studied the efficacy of EPA and EPA/DHA on reducing cardiovascular endpoints, including myocardial infarction (MI), stroke, and CVD-attributable mortality.
